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ABSTRACT
We compared the outcomes of 298 patients with acute lymphoblastic leukemia in first or second complete
remission (CR1 or CR2) receiving HLA-matched sibling allografts after cyclophosphamide and total body
irradiation (Cy-TBI) conditioning with 204 patients receiving etoposide and TBI. Consequently, 4 groups
were compared: Cy-TBI <13 Gy (n  217), Cy-TBI >13 Gy (n  81), etoposide-TBI <13 Gy (n  53), and
etoposide-TBI >13 Gy (n  151). Analyses of relapse, leukemia-free survival (LFS), and survival were
performed separately for CR1 and CR2 transplantations. Transplant-related mortality did not differ by
conditioning regimen. In CR1, there were also no significant differences in relapse, LFS, or survival by
conditioning regimen. In CR2, these outcomes differed among conditioning groups. In comparison with
Cy-TBI <13 Gy, the risks of relapse, treatment failure (inverse of LFS), and mortality tended to be lower with
etoposide (regardless of TBI dose) or with TBI doses >13 Gy. For both CR1 and CR2 transplantations, causes
of death were similar among the groups; disease recurrence accounted for 47% of deaths. We conclude that for
HLA-identical sibling allografts for acute lymphoblastic leukemia in CR2, there is an advantage in substituting
etoposide for Cy or, when Cy is used, in increasing the TBI dose to >13 Gy.
© 2006 American Society for Blood and Marrow Transplantation
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Comparison of Conditioning Regimens for ALL Sibling Allografts
BNTRODUCTION
Allogeneic stem cell transplantation cures hema-
ologic malignancies through 2 major mechanisms.
he pretransplantation conditioning regimen kills
eukemic cells directly, either eradicating the malig-
ancy or reducing it to a minimal residual disease
tate. The second mechanism is a graft-versus-tumor
ffect. The relative importance of these 2 mechanisms
iffers from disease to disease: graft-versus-tumor ef-
ects are most important in chronic myelogenous leu-
emia and less important, although demonstrable, in
cute myelogenous leukemia and acute lymphoblastic
eukemia (ALL) [1]. For patients with ALL, the cyto-
oxic effect of pretransplantation chemoradiotherapy
ay be important in determining outcome. A graft-
ersus-leukemia (GVL) effect may be effective only if
here is a low level of residual disease, given the rapid
inetics of ALL cell growth.
The results of conventional chemotherapy for
dults with ALL are unsatisfactory, and there has been
ittle progress in the last decade. Even though chemo-
herapy fails in most patients, the role of HLA-
atched sibling allografting remains controversial.
n International Bone Marrow Transplant Registry
IBMTR) study showed that HLA-identical sibling
llografting produced a clear survival advantage over
hemotherapy for children with ALL in second com-
lete remission (CR) [2]. In general, only children
ith very-high-risk disease (Philadelphia positive or
nduction failure) receive allografts in ﬁrst CR. For
dults with ALL in second CR, survival after chemo-
herapy alone is so low that allografting seems clearly
uperior [3]. However, the results of allografting for
LL in second CR are far from acceptable, particu-
arly for patients who relapse while receiving therapy.
n young adults with ALL in ﬁrst CR, there are con-
icting data about the value of transplantation. One
BMTR study showed no advantage, but a more re-
ent study showed that transplantation was superior in
ounger adults [4,5]. A recent randomized French
tudy of 284 adults with ALL in ﬁrst CR showed 45%
-year disease-free survival (DFS) with allografting
ompared with 31% with chemotherapy or autograft-
ng (P  .10) [6]. Subgroup analysis suggested a sig-
iﬁcant survival advantage with allogeneic transplan-
ation in patients with high-risk disease features.
The major cause of treatment failure after alloge-
eic transplantation for ALL is relapse. Very few pa-
ients survive this complication. Although there is
vidence for a GVL effect in ALL, the poor results of
onor leukocyte infusions for leukemic relapse after
llografting suggest that this effect may be limited
1,7]. The optimal conditioning regimen before HLA-
atching sibling allografts for patients with ALL is
nknown. Total body irradiation (TBI) is frequently
sed because of the predictable toxicity of radiotherapy v
B & M Tnd its ability to kill leukemic cells in sanctuary sites,
uch as the central nervous system and the testis. Cyclo-
hosphamide (Cy; 120 mg/kg) and TBI (12 Gy in 6
ractions), although developed on empirical observa-
ions, is regarded as the standard regimen. It has been
sed for 30 years and has relatively predictable short-
nd long-term toxicity [8]. In one study, higher doses of
BI seemed to decrease leukemic relapse but, because of
xtramedullary toxicity, did not improve survival [9].
owever, the optimal dose of TBI is not known.
A conditioning regimen of etoposide (60 mg/kg)
nd TBI (13.2 Gy) was ﬁrst evaluated by the Stanford
nd City of Hope (COH) groups and seemed to be
ighly active in patients with leukemia [10]. This
roup subsequently demonstrated considerable activ-
ty of this regimen in patients with advanced acute
eukemia [11]. A German study using the same regi-
en reported 64% DFS at 18 months in 17 high-risk
atients (10 were not in remission at transplantation)
12]. With these encouraging results, the regimen was
hen adopted for patients with less advanced disease.
sing the etoposide-TBI regimen for conditioning,
hese groups reported 64% DFS at 3 years for 34 pa-
ients with ALL in ﬁrst CR and a relapse rate of 12%
13]. These data were updated at the 1999 American
ociety of Hematology meeting by Fung et al.; among
02 patients who underwent transplantation in ﬁrst CR,
FS was 63%, and only 8% died of relapse [14]. Al-
hough the median follow-up of the expanded series was
nly 2.1 years, it is worth noting that relapses were rarely
een more than 2 years after transplantation. Initial re-
ults were sufﬁciently good for the large international
edical Research Council UKALL12/Eastern Cooper-
tive Oncology Group study to adopt this conditioning
egimen as its standard in 1993. A 5-year DFS of 54%
as seen in 170 patients with Philadelphia-negative ALL
onditioned with etoposide-TBI [15]. However, the
00-day transplant-related mortality (TRM) in the
ulticenter, multinational setting was 21% [15].
he Stanford and COH groups found that the eto-
oside-TBI regimen caused considerable mucosal
nd dermatologic toxicity but that TRM was low
13]. The mucositis seen with etoposide-TBI may
esult in less prophylactic methotrexate being given
D. Marks, unpublished data).
Although the best reported results of the etoposide-
BI conditioning seem superior to those achieved with
tandard Cy-TBI, there has never been a study directly
omparing the 2 regimens. Here we report a registry-
ased comparison of the outcome of more than 500
dult and pediatric patients with ALL in ﬁrst or second
R who received either Cy-TBI or etoposide-TBI be-
ore an HLA-matched sibling transplantation. Out-
omes studied were TRM, relapse, leukemia-free sur-
ival (LFS), overall survival, and causes of death.
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4ATIENTS AND METHODS
ata Sources
Data for this study were obtained from 2 sources:
he Center for International Blood and Marrow
ransplant Research (CIBMTR; n  427), which
ools data from many centers, and the COH Cancer
enter (n  75), which did not contribute data to the
IBMTR during the study period.
The CIBMTR is a research afﬁliation of the
BMTR, the Autologous Blood and Marrow Trans-
lant Registry, and the National Marrow Donor Pro-
ram that comprises a voluntary working group of
ore than 450 transplantation centers worldwide that
ontribute detailed data on consecutive allogeneic and
utologous hematopoietic stem cell transplantations
o a statistical center at the Health Policy Institute of
he Medical College of Wisconsin in Milwaukee or
he National Marrow Donor Program Coordinating
enter in Minneapolis, MN. Participating centers are
equired to report all transplantations consecutively;
ompliance is monitored by on-site audits. Patients
re followed up longitudinally, with yearly follow-up.
The CIBMTR collects data at 2 levels: registra-
ion and research. Registration data include disease
ype, age, sex, pretransplantation disease stage and
hemotherapy responsiveness, date of diagnosis, graft
ype (bone marrow–derived and/or blood-derived stem
able 1. Variables Tested in Cox Proportional Hazards Regression Mod
ain effect variable*
Conditioning regimen before transplantation: Cy-TBI, fractiona
Gy vs. etoposide-TBI, fractionated TBI dose >13 Gy vs. Cy-T
atient-related variables
Age at transplantation: <20† vs. >20 y
Sex: female† vs. male
Karnofsky performance status at transplantation: >90%† vs. <9
isease-related variables at diagnosis
Immunophenotype: T-cell† vs. other
WBC at diagnosis: <25  109/L† vs. 25-100  109/L vs. 100-200
Cytogenetics: no abnormalities† vs. hypodiploid, t(9;22), t(4;11
Extramedullary disease: no† vs. yes
isease-related variables at transplantation
Relapse on chemotherapy: no† vs. yes vs. unknown
Time from diagnosis to first complete remission: <4 wk† vs. 4-
Disease status before transplantation: CR1† vs. CR2
Duration of CR1: <12 mo† vs. 12-24 mo vs. 24-36 mo vs. >36
Time from remission to transplantation: <3 mo† vs. >3 mo vs
reatment-related variables
Nucleated cell dose, median (range),  108/kg: continuous‡
Donor age: <20 y† vs. >20 y
Donor-recipient sex match: male-male† vs. female-male vs. ma
Donor-recipient CMV status: /† vs. / vs. / vs. / vs.
Source of stem cells: BM† vs. PBSC
Year of transplantation: 1989-1994† vs. 1995-1998
GVHD prophylaxis: CSP  other† vs. MTX  CSP alone vs. M
BC indicates white blood cell count; CMV, cytomegalovirus; BM
Included in all models.
Reference group for analysis.
Data not available for City for Hope patients.ells), high-dose conditioning regimen, posttransplanta- o
40ion disease progression and survival, development of a
ew malignancy, and cause of death. Requests for data
n progression or death for registered patients are at
-month intervals. All CIBMTR teams contribute
egistration data. Research data are collected on sub-
ets of registered patients and include comprehensive
retransplantation and posttransplantation clinical in-
ormation. Computerized checks for errors, physician
eviews of submitted data, and on-site audits of par-
icipating centers ensure the quality of the data.
The COH Cancer Center is a National Cancer
nstitute–designated Comprehensive Cancer Center
nd one of the largest providers of bone marrow
ransplantation services worldwide. Data for this study
ere provided to the CIBMTR statistical center for all
atients who met the eligibility criteria and underwent
ransplantation during the study period: data were
rospectively collected and maintained by the COH
n its computerized database system.
atients
This study included patients receiving HLA-iden-
ical sibling bone marrow or peripheral blood stem
ell (PBSC) transplants for ALL in ﬁrst or second CR
etween 1989 and 1998 after pretransplantation con-
itioning with Cy-TBI or etoposide-TBI, reported on
omprehensive data collection forms to the CIBMTR
I dose <13 Gy† vs. etoposide-TBI, fractionated TBI dose <13
ctionated TBI dose >13 Gy
unknown
/L vs. >200  109/L vs. missing
4) vs. other abnormalities vs. unknown
s. >8 wk vs. missing
missing
g
ale vs. female-female
g
SP  other
marrow; CSP, cyclosporine; MTX, methotrexate.els
ted TB
BI, fra
0% vs.
 109
), t(8;1
8 wk v
mo vs.
missin
le-fem
missin
TX  C
, boner performed at the COH transplant center. Demo-
Table 2. Characteristics of Patients Receiving HLA-Identical Sibling Transplants for ALL in First or Second Complete Remission by Pretransplantation Conditioning Regimen
Variable
No.
Eval
Cy-TBI
<13 Gy
No.
Eval
Cy-TBI
>13 Gy
No.
Eval
Etoposide-TBI
<13 Gy
No.
Eval
Etoposide-TBI
>13 Gy
P
Value*
No. patients 217 81 53 151
Median (range) age (y) 217 18 (1-56) 81 16 (2-46) 53 12 (2-41) 151 25 (4-54) <.001
Age at transplantation, n (%) 217 81 53 151 <.001
<10 y 60 (28) 29 (36) 24 (45) 12 (8)
11-19 y 64 (29) 22 (27) 15 (28) 38 (25)
20-29 y 47 (22) 18 (22) 10 (19) 45 (30)
30-39 y 30 (14) 10 (12) 3 (6) 37 (24)
>40 y 16 (7) 2 (3) 1 (2) 19 (13)
Male sex, n (%) 217 145 (67) 81 45 (56) 53 39 (74) 151 103 (68) .13
Karnofsky status before transplantation <90%, n (%) 216 36 (17) 78 15 (19) 51 14 (27) 149 27 (18) .36
CRI status at transplantation 217 121 (56) 81 38 (47) 53 24 (45) 151 108 (72) <.001
Immunophenotype, n (%) 217 81 53 151 <.001
T-cell 40 (19) 16 (20) 10 (19) 30 (20)
Mature B-cell 20 (9) 5 (6) 0 8 (5)
Null 13 (6) 7 (9) 4 (7) 5 (3)
CALLa 111 (51) 40 (49) 30 (57) 51 (34)
Other 33 (15) 13 (16) 9 (17) 57 (38)
Median (range) WBC at diagnosis (n  109/L) 199 12 (<1-850) 71 20 (<1-680) 42 17 (1-488) 143 21 (<1-507) .07
WBC at diagnosis, n (%) 199 71 42 143
<25  109/L 125 (63) 38 (53) 22 (52) 76 (53)
25-<100  109/L 46 (23) 17 (24) 13 (31) 38 (27)
100-<200  109/L 13 (6) 9 (13) 2 (5) 13 (9)
>200  109/L 15 (8) 7 (10) 5 (12) 16 (11)
Cytogenetics, n (%) 217 81 53 151 .06
No abnormalities 77 (36) 20 (25) 17 (32) 35 (23)
Hypodiploid, t(9;22), t(4;11); t(8;14)† 29 (13) 6 (7) 6 (11) 30 (20)
Other abnormalities 45 (21) 18 (22) 12 (23) 36 (24)
Unknown 66 (30) 37 (46) 18 (34) 50 (33)
Extramedullary disease at diagnosis or relapse, n (%) 217 65 (30) 81 30 (37) 53 12 (23) 151 56 (37) .16
Site of extramedullary disease at diagnosis, n (%)
CNS 217 11 (5) 77 3 (4) 51 2 (4) 150 9 (6) .89
Testes 216 0 77 1 (1) 51 0 150 0 .14
Mediastinum 217 11 (5) 78 6 (8) 51 3 (6) 150 15 (10) .33
Other 217 33 (15) 78 11 (14) 51 3 (6) 150 14 (9) .16
Site of extramedullary disease at relapse before
treatment, n (%)
CNS 139 8 (6) 51 6 (12) 32 3 (9) 119 14 (12) .34
Other 131 1 (1) 47 0 29 0 112 0 .70
Relapse on chemotherapy, n (%) 214 28 (13) 80 13 (16) 50 9 (18) 150 8 (5) .021
Time from Dx to CRI, n (%) 200 74 48 141 <.001
<4 wk 59 (30) 27 (36) 10 (21) 64 (45)
4-8 wk 106 (53) 30 (41) 20 (42) 60 (43)
>8 wk 35 (17) 17 (23) 18 (37) 17 (12)
Duration of CRI, n (%)‡ 82 37 24 16 .51
<12 mo 22 (27) 8 (21) 5 (21) 2 (13)
12-24 mo 15 (18) 4 (11) 8 (33) 5 (31)
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Table 2. Continued
Variable
No.
Eval
Cy-TBI
<13 Gy
No.
Eval
Cy-TBI
> 13 Gy
No.
Eval
Etoposide-TBI <13
Gy
No.
Eval
Etoposide-TBI >13
Gy
P
Value*
24-36 mo 21 (26) 14 (38) 5 (21) 5 (31)
>36 mo 24 (29) 11 (30) 6 (25) 4 (25)
Median (range) time from remission to
transplantation (d) 211 90 (6-793) 75 117 (9-831) 51 97 (17-325) 147 83 (7-508) .007
Time from remission to transplantation >3 mo, n (%) 211 103 (49) 75 49 (65) 51 28 (55) 147 66 (45) .029
Median (range) nucleated cell dose (n  108/kg)§ 174 3 (.01-18) 63 3 (.02-20) 37 4 (1-41) 74 3 (.02-17) .05
Median (range) donor age (y) 214 17 (<1-52) 80 15 (1-51) 52 15 (1-41) 149 26 (<1-56) <.001
Donor-recipient sex match, n (%) 217 81 53 151 .46
Male-male 85 (39) 24 (29) 20 (38) 57 (38)
Female-male 60 (28) 21 (26) 19 (36) 35 (23)
Male-female 40 (18) 20 (25) 6 (11) 35 (23)
Female-female 32 (15) 16 (20) 8 (15) 24 (16)
Donor-recipient CMV status, n (%) 203 80 50 141 .003
/ 84 (41) 20 (25) 20 (40) 70 (50)
/ 29 (14) 8 (10) 8 (16) 22 (15)
/ 15 (8) 11 (14) 6 (12) 17 (12)
/ 75 (37) 41 (51) 16 (32) 32 (23)
Graft type, n (%) 217 81 53 151 .08
BM 201 (93) 72 (89) 47 (89) 146 (97)
PBSC 16 (7) 9 (11) 6 (11) 5 (3)
Year of transplantation, n (%) 217 81 53 151 .09
1989-1990 40 (18) 6 (8) 3 (6) 23 (15)
1991-1992 28 (13) 18 (22) 11 (21) 30 (20)
1993-1994 38 (18) 13 (16) 10 (19) 35 (23)
1995-1996 56 (26) 26 (32) 17 (32) 36 (24)
1997-1998 55 (25) 18 (22) 12 (22) 27 (18)
Median (range) TBI doses, (Gy) 217 1200 (1200-1206) 81 1440 (1320-1450) 53 1200 (1200-1232) 151 1320 (1320-1440) <.001
Median (range) drug doses, mg/kg 217 6785 (1440-12996) 81 6000 (1560-12800) 50 2340 (638-5292) 77 3900 (540-6660) NA
GVHD prophylaxis, n (%) 217 81 53 151 <.001
CsA alone 37 (17) 13 (16) 2 (3) 7 (5)
CsA  steroids 8 (4) 7 (9) 4 (8) 25 (16)
CsA  other 1 (<1) 1 (1) 0 1 (1)
MTX  CsA alone 160 (74) 56 (69) 43 (81) 36 (24)
MTX  CsA  steroids 8 (4) 3 (4) 4 (8) 76 (50)
MTX  CsA  other 3 (1) 1 (1) 0 6 (4)
Intrathecal therapy,¶ n (%) 228 16 (7) 77 10 (13) 50 2 (4) 148 34 (23) <.001
Median (range) follow-up survivors (mo) 67 (8-156) 59 (17-149) 52 (7-144) 65 (3-156)
Eval indicates evaluable; ALL, acute lymphoblastic leukemia; Cy, cyclophosphamide; TBI, total body irradiation; CR, complete remission; WBC, white blood cells; CNS, central nervous system; BM,
bone marrow; PBSC, peripheral blood stem cells; GVHD, graft-versus-host disease; CSA, cyclosporine; MTX, methotrexate; Dx, diagnosis; CMV, cytomegalovirus; cALLa, common acute
lymphoblastic leukemia antigen.
*The 2 test was used for discrete covariates; the Kruskal-Wallis test was used for continuous covariates.
†Thirty-four (49%) of these patients had t(9;22).
‡For patients in CR2.
§Data not available for City of Hope patients.
Other GVHD prophylaxis treatments were antithymocyte globulin, azathioprine, and in vivo anti T-lymphocyte monoclonal antibody.
¶None of these patients received immune therapy posttransplant.
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Comparison of Conditioning Regimens for ALL Sibling Allografts
Braphics and survival of the study population were
imilar to all ALL patients in CR1 or CR2 registered
ith the CIBMTR during the study period. Patients
ho received T cell–depleted grafts, methotrexate
ithout cyclosporin A as graft-versus-host disease
GVHD) prophylaxis, nonfractionated TBI, or TBI
ractionated doses 12 or 14.5 Gy were excluded
rom the analysis. Cy doses ranged from 100 to 130
g/kg, and etoposide doses ranged from 40 to 60
g/kg. Five hundred two patients met the on-study
riteria: 217 patients received Cy-TBI 13 Gy, 81
atients received Cy-TBI 13 Gy, 53 patients re-
eived etoposide-TBI 13 Gy, and 151 received eto-
oside-TBI 13 Gy. COH did not routinely report
ases to the CIBMTR during the years 1989 to
998. However, COH provided the necessary data
o the CIBMTR for 75 patients who received
toposide-TBI 13 Gy as their conditioning regimen
uring this period.
Eligible cases came from 111 reporting teams.
he median follow-up of survivors was 67 months
range, 8-156 months) for Cy-TBI 13 Gy patients,
9 months (range, 17-149 months) for Cy-TBI 13
y patients, 52 months (range, 7-144 months) for
toposide-TBI 13 Gy patients, and 65 months
range, 3-156 months) for etoposide-TBI 13 Gy
able 3. Univariate Analyses of Transplantation Outcomes among Pati
emission by Pretransplantation Conditioning Regimen
Outcome Event
Cy-TBI <13 Gy Cy-T
No. Eval Prob (95% CI) No. Eval
ulmonary toxicity, n (%) 121 34 (28) 35
rade II-IV acute GVHD
at 100 d 121 29 (21-38) 36
hronic GVHD 120 38
At 1 y 23 (16-32)
At 3 y 28 (20-38)
At 5 y 30 (21-39)
00-d mortality 121 8 (4-14) 38
RM 118 36
At 1 y 9 (5-15)
At 3 y 12 (7-18)
At 5 y 13 (7-19)
elapse 118 36
At 1 y 23 (15-31)
At 3 y 32 (24-41)
At 5 y 33 (24-42)
FS 118 36
At 1 y 68 (59-76)
At 3 y 56 (47-65)
At 5 y 54 (45-63)
verall survival 121 38
At 1 y 74 (65-81)
At 3 y 59 (50-68)
At 5 y 55 (46-64)
rob indicates probability; CI, conﬁdence interval; Eval, evaluabl
transplant-related mortality; Cy, cyclophosphamide; TBI, total
robabilities of 100-day mortality, leukemia-free survival, and ov
estimate. Acute GVHD, chronic GVHD, relapse, and TRM watients. c
B & M Tnd Points
Primary end points were TRM, clinical leukemia
elapse (hematologic and extramedullary), LFS, and
verall survival. TRM was deﬁned as death during a
ontinuous CR. Relapse was deﬁned as clinical or
ematologic leukemia recurrence. For analyses of
FS, failures were leukemia relapses or deaths from
ny cause; patients alive and in CR were censored at
he time of last follow-up. For analyses of overall
urvival, failure was death from any cause; surviving
atients were censored at the date of last contact.
tatistical Analysis
Patient-, disease-, and transplant-related variables
or patients receiving Cy-TBI 13 Gy, Cy-TBI 13
y, etoposide-TBI 13 Gy, and etoposide-TBI 13
y for the conditioning regimen were compared by
sing the 2 statistic for categorical variables and the
ruskal-Wallis test for continuous variables. Univar-
ate probabilities of LFS and survival were calculated
y using the Kaplan-Meier estimator; the log-rank
est was used for univariate comparisons. Probabilities
f TRM and leukemia relapse were calculated by us-
ng cumulative incidence curves to accommodate
ceiving HLA-Identical Sibling Transplants for ALL in First Complete
Gy Etoposide-TBI <13 Gy Etoposide-TBI >13 Gy
(95% CI) No. Eval Prob (95% CI) No. Eval Prob (95% CI)
(26) 23 7 (30) 108 40 (37)
(11-39) 24 30 (14-50) 106 25 (17-34)
22 93
(10-40) 19 (4-42) 34 (24-45)
(13-45) 19 (4-42) 42 (32-53)
(13-45) 19 (4-42) 44 (33-55)
(4-26) 24 21 (7-39) 108 12 (7-19)
21 108
(4-26) 23 (8-43) 9 (5-15)
(8-33) 27 (10-48) 10 (5-17)
(8-33) 27 (10-48) 12 (6-19)
21 108
(6-30) 9 (8-25) 12 (7-19)
(11-40) 13 (5-31) 23 (15-31)
(14-45) 13 (2-31) 27 (19-36)
21 108
(54-83) 67 (46-85) 79 (70-86)
(39-71) 57 (36-77) 67 (58-76)
(35-68) 57 (36-77) 61 (51-70)
24 108
(59-86) 71 (51-87) 80 (71-87)
(47-77) 61 (41-80) 67 (58-75)
(44-75) 61 (41-80) 62 (52-71)
, leukemia-free survival; GVHD, graft-versus-host disease; TRM,
radiation; ALL, acute lymphoblastic leukemia.
rvival were calculated by using the Kaplan-Meier product-limit
ulated by using the cumulative incidence estimate.ents Re
BI >13
Prob
9
24
23
27
27
13
13
19
19
16
24
28
69
56
51
74
63
60
e; LFS
body ir
erall suompeting risks [16]. Assessment of potentially con-
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4ounding risk factors for outcomes of interest was
erformed by using Cox proportional hazards regres-
ion [17]. Variables considered are listed in Table 1.
irst, we compared the likelihood from a model
tratiﬁed on conditioning regimen to a model with
ifferent risk coefﬁcients for each conditioning reg-
men. The likelihood ratio test constructed from
hese models determined whether there was an in-
eraction between the conditioning regimen and the
actor being examined. When the likelihood ratio test
as signiﬁcant, an interaction term was added to the
odel. We found an interaction between conditioning
egimen drug and TBI dose, so ﬁnal models included
ain effect terms reﬂecting the conditioning regimen
ccording to levels of TBI dose. The median TBI dose
13 Gy) was used as the cutoff point for high versus
ow dose. Additionally, the Martingale residuals plot
as used to verify the validity of this cutoff point [17].
owever, for relapse, LFS, and survival, this interac-
ion was restricted to patients receiving Cy; conse-
uently, patients receiving etoposide were considered
s a single group. We also found an interaction be-
ween conditioning regimen and disease status before
ransplantation for all outcomes except TRM; conse-
uently, analyses of relapse, LFS, and survival consid-
able 4. Univariate Analyses of Transplantation Outcomes among Pati
omplete Remission by Pretransplant Conditioning Regimen
Outcome Event
Cy-TBI <13 Gy Cy-T
No. Eval Prob (95% CI) No. Eval
ulmonary toxicity, n (%) 96 32 (33) 43
rade II-IV acute GVHD
at 100 d 96 33 (24-83) 39
hronic GVHD 94 43
At 1 y 22 (14-32)
At 3 y 25 (16-35)
At 5 y 25 (16-35)
00-d mortality 96 18 (11-26) 43
RM 95 43
At 1 y 18 (11-26)
At 3 y 18 (11-26)
At 5 y 20 (13-29)
elapse 95 43
At 1 y 30 (21-40)
At 3 y 42 (31-53)
At 5 y 46 (34-57)
FS 95 43
At 1 y 51 (41-61)
At 3 y 40 (30-50)
At 5 y 33 (24-43)
verall survival 96 43
At 1 y 64 (55-74)
At 3 y 48 (38-58)
At 5 y 40 (30-51)
rob indicates probability; CI, conﬁdence interval; Eval, evaluabl
transplant-related mortality; Cy, cyclophosphamide; TBI, total
robabilities of 100-day mortality, leukemia-free survival, and ov
estimate. Acute GVHD, chronic GVHD, relapse, and TRM wred conditioning regimen effects separately for trans- h
44lantations performed in ﬁrst and second CR. After
etermining interaction terms, we next tested for pro-
ortional hazards for each factor in the Cox model by
sing time-dependent covariates. When this indicated
ifferential effects over time (nonproportional haz-
rds), models were constructed by breaking the post-
ransplantation course into 2 time periods. The max-
mized partial likelihood method was used to ﬁnd the
ost appropriate breakpoint. After this modeling of
ime varying effects, the ﬁnal multivariate model was
uilt by using a forward stepwise model selection
pproach. Each model contained the main effect for
he conditioning regimen (Cy-TBI 13 Gy versus
y-TBI13 Gy versus etoposide-TBI13 Gy versus
toposide-TBI 13 Gy). Factors that were signiﬁcant
t a 5% level were kept in the ﬁnal model. Because, in
hese models, TBI dose did not seem to affect relapse,
FS, or survival when combined with etoposide, ad-
itional analyses of these outcomes were also per-
ormed that considered 3 groups: Cy-TBI 13 Gy
ersus Cy-TBI13 Gy versus etoposide-TBI. To test
or possible center effects, a random effects score test
eveloped by Andersen et al. [18] was used. The test is
erformed on the ﬁnal model for the study and tests
he hypothesis that there is no center effect against the
ceiving HLA-Identical Sibling Transplants for ALL in Second
Gy Etoposide-TBI <13 Gy Etoposide-TBI >13 Gy
(95% CI) No. Eval Prob (95% CI) No. Eval Prob (95% CI)
(37) 29 6 (21) 43 15 (35)
(27-58) 29 36 (19-54) 39 24 (12-39)
27 34
(14-44) 31 (14-51) 37 (21-54)
(17-50) 37 (18-58) 37 (21-54)
(17-50) 37 (18-58) 37 (21-54)
(7-29) 29 10 (2-24) 43 16 (7-29)
29 43
(10-34) 10 (2-23) 9 (2-19)
(10-34) 10 (2-23) 9 (2-19)
(10-34) 10 (2-23) 12 (4-24)
29 43
(4-22) 21 (8-38) 29 (16-44)
(5-26) 24 (10-42) 36 (22-52)
(7-30) 33 (16-54) 36 (22-52)
29 43
(53-80) 68 (50-84) 60 (46-74)
(50-78) 64 (46-81) 54 (39-69)
(46-76) 54 (35-73) 50 (35-65)
29 43
(63-88) 75 (58-89) 67 (53-80)
(58-84) 71 (53-86) 53 (39-68)
(58-84) 56 (36-75) 50 (35-65)
leukemia-free survival; GVHD, graft-versus-host disease; TRM,
radiation; ALL, acute lymphoblastic leukemia.
rvival were calculated by using the Kaplan-Meier product-limit
ulated by using the cumulative incidence estimate.ents Re
BI >13
Prob
16
42
28
32
32
16
20
20
20
11
14
17
67
65
62
77
72
72
e; LFS,
body ir
erall suypothesis of a random center effect. We found no
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Bvidence of a correlation between center and any of
he outcomes. All P values are 2 sided.
ESULTS
atients
The patients in the 4 conditioning groups were
ompared with respect to demographic factors and
ther prognostic variables known to inﬂuence out-
ome (Table 2). The proportion of patients over the
ge of 30 years was higher in the etoposide-TBI 13
y group. Adverse cytogenetic abnormalities [hypo-
iploid, t(9;22), t(4;11), and t(8;14)] were also slightly
igure 1. Cumulative incidence of TRM after HLA-identical siblin
ccording to the pretransplantation conditioning regimen (pointw
y-TBI 13 Gy, P  .49; etoposide-TBI 13 Gy versus Cy-TBI
 .14; Cy-TBI 13 Gy versus Cy-TBI 13 Gy, P  .40; Cy-TB
toposide-TBI 13 Gy, P  .81; pointwise P value at 5 years for
toposide-TBI 13 Gy versus Cy-TBI 13 Gy, P  .14; etoposid
ersus Cy-TBI 13 Gy, P  .98; Cy-TBI 13 Gy versus etoposide
 .22). Vp16 indicates etoposide.ore common in this group. Additionally, the eto- g
B & M Toside-TBI 13 Gy group had a smaller proportion
f transplantations for which both donor and recip-
ent were cytomegalovirus seronegative. More than
alf of the etoposide-TBI 13 Gy group received
orticosteroids in addition to standard cyclosporine
nd methotrexate GVHD prophylaxis, whereas this
ethod of GVHD prophylaxis was uncommonly
sed in the other 3 conditioning groups. This made
t difﬁcult to separate the effects of differing GVHD
rophylaxis from conditioning regimens on out-
ome. The etoposide-TBI 13 Gy group had a
igher percentage of patients who took 8 weeks to
chieve remission (37% versus 17% in the other 3
plantations for ALL in ﬁrst (A) or second (B) complete remission,
alue at 5 years for CR1 patients: etoposide-TBI 13 Gy versus
y, P  .17; etoposide-TBI 13 Gy versus etoposide-TBI 13 Gy,
y versus etoposide-TBI 13 Gy, P  .33; Cy-TBI 13 Gy versus
atients: etoposide-TBI 13 Gy versus Cy-TBI 13 Gy, P  .21;
13 Gy versus etoposide-TBI 13 Gy, P  .79; Cy-TBI 13 Gy
13 Gy, P  .30; Cy-TBI 13 Gy versus etoposide-TBI 13 Gy,g trans
ise P v
13 G
I 13 G
CR2 p
e-TBI 
-TBI roups combined).
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4nivariate Analyses
The major transplantation outcomes in the 4 con-
itioning groups are compared in Tables 3 and 4.
hese data require cautious interpretation because of
he differences in patient characteristics described
reviously. There were no major differences in pul-
onary toxicity or 100-day mortality. Among patients
ho underwent transplantation in CR1, chronic
VHD was more common at 5 years in the etopo-
ide-TBI 13 Gy group. This difference occurred
espite no differences in the incidences of grade II
o IV or III/IV acute GVHD (data not shown).
RM was also somewhat lower in the etoposide-
BI 13 Gy groups (Figure 1). The highest risks of
elapse (Figure 2) and the lowest probabilities of
FS and overall survival were in the Cy-TBI 13
igure 2. Cumulative incidence of relapse after HLA-identical sibli
ccording to the pretransplantation conditioning regimen (pointwis
y, P  .23; etoposide-TBI versus Cy-TBI 13 Gy, P  .78; Cy-T
or CR2 patients: etoposide-TBI versus Cy-TBI 13 Gy, P  .22;
y-TBI 13 Gy, P  .001). Vp16 indicates etoposide.y groups. A
46ultivariate Analyses
Transplant-related mortality. There was not a sta-
istically signiﬁcant difference in TRM according to
onditioning regimen (overall P  .05), although,
mong patients receiving 13 Gy TBI, there was a
rend for lower TRM with etoposide versus with Cy
Table 5). Other factors signiﬁcantly associated with
igher TRM in multivariate analysis were age 20
ears and receiving a PBSC rather than a bone mar-
ow graft.
Relapse. Among patients who underwent trans-
lantation in CR1, there was not a signiﬁcant associ-
tion between conditioning regimen and relapse risk
overall P  .05), although there was a trend toward
ower relapse in patients receiving etoposide com-
ared with those receiving Cy-TBI13 Gy (Table 6).
splantations for ALL in ﬁrst (A) or second (B) complete remission,
ue at 5 years for CR1 patients: etoposide-TBI versus Cy-TBI 13
3 Gy versus Cy-TBI 13 Gy, P  .60; pointwise P value at 5 years
de-TBI versus Cy-TBI 13 Gy, P  .033; Cy-TBI 13 Gy versusng tran
e P val
BI 1
etoposimong patients who underwent transplantation in
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BR2, relapse risk differed by conditioning regimen.
here was a modest (not statistically signiﬁcant) de-
rease in relapse in the groups that received etoposide
or conditioning. Among patients who received eto-
oside, there was no signiﬁcant difference between
hose who received 13 and 13 Gy of TBI. Among
atients who received Cy for conditioning, the risk of
elapse was signiﬁcantly lower among those who re-
eived 13 Gy of TBI (P  .0016). Other factors
ssociated with an increased risk of relapse in multi-
able 5. Multivariate Analysis Comparing Transplant-Related Mortal
ymphoblastic Leukemia in First or Second Complete Remission
Variable n
onditioning regimen
(1) Cy-TBI, TBI dose <13 Gy 213
(2) Cy-TBI, TBI dose >13 Gy 79
(3) Etoposide-TBI, TBI dose <13 Gy 50
(4) Etoposide-TBI, TBI dose >13 Gy 151
ther significant covariates
Age (y)
<20 260
>20 233
Graft type
Bone marrow 458
Peripheral blood 35
y indicates cyclophosphamide; TBI, total body irradiation.
Reference group.
Three degrees of freedom.
Other pairwise comparisons: 4 versus 2: relative risk  0.42 (0.21
able 6. Multivariate Analysis Comparing Relapse after Etoposide-TBI
irst or Second Complete Remission
Variable n
onditioning regimen
First CR status at transplantation
(1) Cy-TBI, TBI dose <13 Gy 118
(2) Cy-TBI, TBI dose >13 Gy 36
(3) Etoposide-TBI 129
Second CR status at transplantation
(1) Cy-TBI, TBI dose <13 Gy 95
(2) Cy-TBI, TBI dose >13 Gy 43
(3) Etoposide-TBI 72
ther significant covariates
Age (y)
<20 260
>20 233
Cytogenetics
No abnormalities 147
Hypodiploid, t(9;22), t(4;11); t(8;14) 67
Other abnormalities 110
Unknown 169
y indicates cyclophosphamide; TBI, total body irradiation; CR, c
Reference group.
Three degrees of freedom.
Other pairwise comparisons: ﬁrst CR: 3 versus 2: relative risk (RR)
P  .04.
Comparison of etoposide 13 Gy versus etoposide 13 Gy: ﬁrstP  .94.
B & M Tariate analysis were age 20 years and the presence
f cytogenetic abnormalities.
Leukemia-free survival. Among patients who un-
erwent transplantation in CR1, there was little dif-
erence in the risk of treatment failure (inverse of
FS) by conditioning regimen (overall P value .05;
able 7; Figure 3). Among patients who underwent
ransplantation in CR2, the risk of treatment failure
iffered by conditioning regimen (overall P value 
001). There was a lower treatment failure rate with
Etoposide-TBI Versus Cy-TBI Conditioning Regimen for Acute
Relative Risk
(95% Confidence Interval) P Value
1.00* Poverall  .0725†‡
1.36 (0.76-2.42) P12  .3054
1.23 (0.58-2.60) P13  .5877
0.57 (0.32-1.02) P14  .0571
1.00*
2.21 (1.37-3.55) .0011
1.00*
2.03 (1.06-3.89) .0332
P  .012; 4 versus 3: relative risk  0.46 (0.20-1.07), P  .071.
Cy-TBI Conditioning Regimen for Acute Lymphoblastic Leukemia in
Relative Risk
(95% Confidence Interval) P Value
1.00* Poverall  .0632†‡
1.06 (0.54-2.09) P12  .8703
0.58 (0.36-0.94) P13  .0278§
1.00* Poverall  .0045†‡
0.29 (0.14-0.63) P12  .0016
0.67 (0.41-1.09) P13  .1030§
1.00*
1.57 (1.10-2.24) .0131
1.00* Poverall  .0042†
2.17 (1.27-3.71) .0044
1.80 (1.17-2.78) .0076
1.13 (0.74-1.72) .5784
e remission.
(0.27-1.13), P .10; second CR: 3 versus 2: RR 2.28 (1.03-5.04),
 1.16 (0.35-3.86), P  .81; Second CR: RR  1.03 (0.47-2.76),ity afterVersus
omplet
 0.55
CR: RR447
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4se of etoposide in comparison to Cy-TBI 13 Gy
P  .007). Among patients receiving etoposide, there
as no signiﬁcant difference between those receiving
13 and 13 Gy of TBI. Among patients receiving
y for conditioning, the treatment failure rate was
igniﬁcantly lower among those receiving 13 Gy of
BI (P  .0013). Other factors associated with poorer
FS were age 20 years, a poor performance score
efore transplantation, and the use of PBSCs rather
han bone marrow.
Overall survival. Among patients who underwent
ransplantation in CR1, there was little difference in
verall survival by conditioning regimen (overall P
alue .05; Table 8; Figure 4). Among those who
nderwent transplantation in CR2, survival differed
y conditioning regimen (overall P value  .001).
here was higher survival in the group receiving eto-
oside compared with those receiving Cy-TBI 13
y (P  .024). Among patients receiving etoposide,
here was no signiﬁcant difference between those re-
eiving 13 and 13 Gy of TBI. Among those re-
eiving Cy for conditioning, there was higher survival
ith 13 Gy of TBI (P  .0005). Other factors
ssociated with increased mortality in multivariate
nalysis were age20 years, a poor performance score
efore transplantation, and the use of PBSCs rather
able 7. Multivariate Analysis Comparing Leukemia-Free Survival af
eukemia in First or Second Complete Remission
Variable n
onditioning regimen
First CR status at transplantation
(1) Cy-TBI, TBI dose <13 Gy 118
(2) Cy-TBI, TBI dose >13 Gy 36
(3) Etoposide-TBI 129
Second CR status at transplantation
(1) Cy-TBI, TBI dose <13 Gy 95
(2) Cy-TBI, TBI dose >13 Gy 43
(3) Etoposide-TBI 72
ther significant covariates
Age (y)
<20 260
>20 233
Karnofsky status before transplantation
>90% 90
<90% 396
Unknown 7
Graft type
Bone marrow 458
PBSC 35
y indicates cyclophosphamide; TBI, total body irradiation; CR, c
Reference group.
Three degrees of freedom.
Other pairwise comparisons: ﬁrst CR: 3 versus 2: relative risk (RR)
P  .28.
Comparison of etoposide 13 Gy versus etoposide 13 Gy: ﬁrst
P  .74.
Two degrees of freedom.han bone marrow. c
48ther Factors Potentially Affecting
ransplantation Outcomes
The knowledge that most patients in the etopo-
ide-TBI 13 Gy group underwent transplantation
t the Stanford or COH institutions led us to per-
orm an analysis of the center effect (see “Patients
nd Methods”). There was a nonsigniﬁcant trend
oward a center effect (P  .07). We did not ﬁnd
ny interaction between age at transplantation and
onditioning regimen for any of the major out-
omes. Patients younger and older than 20 years
ad similar results; there was insufﬁcient power to
etect differences among smaller age-deﬁned
roups. Chronic GVHD did not signiﬁcantly affect
elapse, LFS, or overall survival.
auses of Death
The major single cause of death was recurrence of
isease (Table 9). Overall, the causes of death were
imilar in the 4 groups except that recurrent disease
as somewhat more common as a cause of death in the
y-TBI 13 Gy group. GVHD, infection, interstitial
neumonia, and organ failure were the other major
oside-TBI Versus Cy-TBI Conditioning for Acute Lymphoblastic
Relative Risk of Relapse or Death
(95% Confidence Interval) P Value
1.00* Poverall  .0758†‡
1.31 (0.77-2.21) P12  .3202
0.73 (0.50-1.08) P13  .1146§
1.00* Poverall  .0011†‡
0.40 (0.23-0.70) P12  .0013
0.56 (0.37-0.85) P  .0065§
1.00*
1.69 (1.27-2.25) .0003
1.00* Poverall  .0057
1.68 (1.22-2.30) .0013
0.57 (0.14-2.35) .4375
1.00*
1.68 (1.07-2.66) .0163
e remission; PBSC, peripheral blood stem cells.
(0.33-0.96), P .03; second CR: 3 versus 2: RR 1.38 (0.77-2.48),
 0.64 (0.31-1.33), P  .23; second CR: RR  1.13 (0.56-2.26),ter Etop
omplet
 0.56
CR: RRauses of treatment failure.
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BISCUSSION
There have been many attempts to intensify con-
itioning regimens to increase leukemia cell kill and
mprove outcomes after transplantation, but few have
een conclusively shown to be successful [19]. Alloge-
eic stem cell transplantation for patients with leuke-
ia, in part, exerts its curative effect via immune
ecognition of host leukemia cells by alloreactive do-
or T cells and other accessory cells. However, be-
ause the GVL effect in ALL seems to be less, the
yeloablative conditioning regimen chosen is also rel-
vant. In addition to providing immune suppression
ufﬁcient for engraftment, cytoreduction may be nec-
ssary to produce a minimal residual disease state so
hat the immunologic properties of the graft may be
ore effective. Overt ALL, or even ALL at the min-
igure 3. Adjusted probability (derived from multivariate regressio
rst (A) or second (B) complete remission, according to the pretra
atients: etoposide-TBI versus Cy-TBI 13 Gy, P  .21; etoposid
13 Gy, P  .59; pointwise P value at 5 years for CR2 patients:
y-TBI 13 Gy, P  .23; Cy-TBI 13 Gy versus Cy-TBI 13 Gmal residual disease level, is seldom eradicated by t
B & M Tllogeneic transplantation, probably because immune
ecognition is insufﬁciently rapid and powerful to
vercome the rapid growth kinetics [20]. Chemora-
iotherapeutic conditioning regimens may also inﬂu-
nce GVHD (and, hence, GVL) by causing tissue
amage and secondary cytokine release; these effects
ay differ between conditioning regimens.
This article provides evidence that the condition-
ng regimen is of importance, particularly for patients
ho undergo transplantation after failure of initial
hemotherapy. In 500 patients with ALL in ﬁrst or
econd CR who received either Cy-TBI or etoposide-
BI conditioning, signiﬁcant interactions between
y, etoposide, and the TBI dose used were found.
he pretransplantation conditioning regimen used
ost widely is Cy and 12 Gy of TBI. In fact, nearly
ls) of LFS after HLA-identical sibling transplantations for ALL in
ation conditioning regimen (pointwise P value at 5 years for CR1
versus Cy-TBI 13 Gy, P  .17; Cy-TBI 13 Gy versus Cy-TBI
de-TBI versus Cy-TBI 13 Gy, P  .002; etoposide-TBI versus
.001). Vp16 indicates etoposide.n mode
nsplant
e-TBI
etoposihree quarters of the patients in this registry-based
449
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4tudy received 13 Gy of TBI. Although differences
n outcome associated with the conditioning regimen
ere minor in patients who underwent transplantation
n CR1, this standard Cy-TBI regimen was associated
ith signiﬁcantly poorer outcomes (relapse, survival,
nd LFS) in patients who underwent transplantation
n CR2. The reduction in survival (10%-32%) com-
ared with the other 3 regimens was of a magnitude
hat would be clinically important and resulted mainly
rom an increased probability of relapse. It was true
or children and adults and for patients with and with-
ut prior extramedullary disease. Excluding Philadel-
hia-positive cases also did not affect the analysis of
utcomes. Although imatinib, which was not available
uring this study period, may produce more durable
emissions in Philadelphia-positive ALL and affect the
utcome of a subsequent transplantation, it is uncer-
ain how it might modify the effect of a conditioning
egimen.
The ﬁndings concerning TBI doses are different
rom those in the randomized Seattle study in patients
ho had allografts for acute myelogenous leukemia. In
hat study, 15.75 Gy was not superior to 12 Gy in
erms of survival [9]. It should be noted that the dose
anges we examined were different, and, of course, the
able 8. Multivariate Analysis Comparing Survival after Etoposide-TB
irst or Second Complete Remission
Variable n
onditioning regimen
First CR status at transplantation
(1) Cy-TBI, TBI dose <13 Gy 121
(2) Cy-TBI, TBI dose >13 Gy 38
(3) Etoposide-TBI 132
Second CR status at transplantation
(1) Cy-TBI, TBI dose <13 Gy 96
(2) Cy-TBI, TBI dose >13 Gy 43
(3) Etoposide-TBI 72
ther significant covariates
Age (y)
<20 264
>20 238
Karnofsky status before transplantation
>90% 92
<90% 402
Unknown 8
Graft type
Bone marrow 466
PBSC 36
y indicates cyclophosphamide; TBI, total body irradiation; CR, c
Reference group.
Three degrees of freedom.
Other pairwise comparisons: ﬁrst CR: 3 versus 2: relative risk (RR)
P  .07.
Comparison of etoposide 13 Gy versus etoposide 13 Gy: ﬁrst
P  .41.
Two degrees of freedom.isease we examined was ALL. Additionally, more of m
50he patients in our study were younger than 18 years;
dverse effects of TBI may be less in this age group.
A surprising ﬁnding of the study is that the TRM
as lower in the group that received etoposide and
BI 13 Gy on univariate analysis, although on mul-
ivariate analysis this was only a trend (P  .06). A
ossible explanation is that this is due to a center
ffect: ie, the TRM may be lower at the COH and
tanford centers. However, analysis did not ﬁnd evi-
ence for a statistically signiﬁcant center effect. We
re not able to explain this effect on TRM. This
orderline effect on TRM may have affected overall
urvival, but it is also worth noting that this regimen
esulted in signiﬁcantly less relapse in CR1 patients.
There is concern, particularly among pediatri-
ians, about the long-term neuropsychological and
rowth/endocrine effects of using TBI. Two regimens
ecently introduced for pediatric patients with ALL
eem to be associated with low relapse rates even in
eavily pretreated patients with multiply relapsed dis-
ase. The ﬁrst, pioneered by the Gluckman group in
aris, combines TBI with melphalan and cytarabine
the TAM regimen) [21]. However, despite low re-
apse rates, overall survival with this regimen does not
eem to be better than with other preparative regi-
s Cy-TBI Conditioning Regimen for Acute Lymphoblastic Leukemia in
Relative Risk of Death
(95% Confidence Interval) P Value
1.00* Poverall  .2534†‡
1.07 (0.61-1.87) P12  .8126
0.75 (0.51-1.10) P13  .1385§
1.00* Poverall  .0010†‡
0.32 (0.17-0.61) P12  .0005
0.60 (0.39-0.93) P13  .0236§
1.00*
1.84 (1.36-2.47) <.0001
1.00* Poverall  .0019
1.77 (1.28-2.44) .0005
0.96 (0.30-3.08) .9416
1.00*
1.82 (1.15-2.88) .0108
e remission; PBSC, peripheral blood stem cells.
(0.40-1.24), P .22; second CR: 3 versus 2: RR 1.86 (0.96-3.63),
 0.71 (0.34-1.48), P  .36; second CR: RR  1.37 (0.65-2.85),I Versu
omplet
 0.70
CR: RRens. The second regimen combines TBI with high-
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Bose cytarabine (36 gm/m2). Again, very low relapse
ates are reported, but regimen-related toxicity limits
ong term survival [22]. Although TBI-containing reg-
mens are the gold standard, many pediatric transplant
enters now use a busulfan-Cy regimen to avoid radi-
tion-related adverse effects. Engraftment rates are
imilar, but relapse rates are higher, and TRM is no
ess than with other regimens. A recently concluded
andomized study comparing a busulfan-Cy regimen
ith a TBI-containing regimen showed inferior sur-
ival results with the non-TBI approach [23].
Another ﬁnding of this study was lower leukemia-
ree and overall survival in the small number of pa-
ients who received a PBSC graft. PBSC transplants
ere associated with higher TRM but a similar
elapse risk. Reasons for these ﬁndings are not ap-
igure 4. Adjusted probability (derived for multivariate regression m
LL in ﬁrst (A) or second (B) complete remission, according to the
R1 patients: etoposide-TBI versus Cy-TBI 13 Gy, P  .18; et
y-TBI 13 Gy, P  .87; pointwise P value at 5 years for CR2 p
ersus Cy-TBI 13 Gy, P  .012; Cy-TBI 13 Gy versus Cy-TBarent, and they may be due to chance alone. Ben- p
B & M Tﬁcial effects of using PBSC are more easily seen in
atients with advanced leukemia, but it was surprising
hat this group of patients had a worse outcome in our
eries [24].
This study has limitations. TBI is given in many
ifferent ways with different fractionation, dose rates,
se of compensators, and variable lung shielding. The
IBMTR did not have these speciﬁc data available for
ll patients. Thus, there may be considerable variation
n the effective biological dose administered. The
ethod of administering TBI may inﬂuence outcome.
or example, both Stanford and COH administer 13.2
y in 11 fractions, shielding the lungs from half the
otal dose but administering electron beam radiation
o the bony structures of the thorax [25]. This study
lso lacks data about the precise doses of GVHD
of overall survival after HLA-identical sibling transplantations for
splantation conditioning regimen (pointwise P value at 5 years for
e-TBI versus Cy-TBI 13 Gy, P  .47; Cy-TBI 13 Gy versus
etoposide-TBI versus Cy-TBI 13 Gy, P  .029; etoposide-TBI
Gy, P  .001). Vp16 indicates etoposide.odels)
pretran
oposid
atients:rophylaxis received. It is possible that patients in the
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4igh-dose TBI groups received less methotrexate (be-
ause of mucositis) and that this may be the mecha-
ism of the protection against relapse. However, in
his study, acute and chronic GVHD were not asso-
iated with a reduction in relapse probability.
This study found less treatment failure and mor-
ality with etoposide, regardless of TBI dose, com-
ared with the standard Cy-TBI 13 Gy TBI regi-
en, accounted for by modest, not individually
tatistically signiﬁcant, reductions in both TRM and
elapse. Although only a randomized study would def-
nitely resolve this issue, such a study would be difﬁ-
ult, given the relatively small numbers of patients
ho undergo transplantation for ALL annually and
he need to standardize TBI techniques across many
enters. After the encouraging results achieved by the
tanford and COH groups, the large UK Medical
esearch Council/US Eastern Cooperative Oncology
roup study of adult ALL adopted etoposide-TBI as
ts standard conditioning regimen.
There are other important differences between Cy
nd etoposide. The dose-limiting toxicity of Cy is
ardiotoxicity [26]. For etoposide, the major limiting
oxicities are stomatitis and hepatotoxicity [10]. How-
ver, this study did not ﬁnd evidence of excess TRM
fter etoposide-TBI. The incidence and type of sec-
ndary malignancies to be expected after Cy-TBI have
een described in a number of studies, whereas there
re no large-scale data available for etoposide-TBI
27]. Secondary leukemias involving 11q23 chromo-
omal abnormalities may be a signiﬁcant long-term
omplication of etoposide.
In summary, this study suggests that the condi-
ioning regimen of Cy and 13 Gy of TBI results in
nferior survival compared with the other 3 condition-
ng regimens studied in patients receiving HLA-iden-
ical sibling allografts for ALL in CR2. We conclude
hat among patients receiving HLA-identical sibling
llografts for ALL in CR2, there seems to be an
dvantage to substituting etoposide for Cy in the con-
able 9. Causes of Death among Patients Receiving HLA-Identical Sib
retransplantation Conditioning Regimen
Cause of Death
No.
Eval
Cy-TBI
<13 Gy
No.
Eval
o. patients 112 28
ecurrence disease 63 (56)
VHD 11 (10)
raft failure 0
nfection 11 (10)
nterstitial pneumonia 7 (6)
RDS 3 (2)
rgan failure 4 (4)
emorrhage 3 (3)
ther/missing 10 (9)
VHD indicates graft-versus-host disease; ARDS, adult respiratoritioning regimen or, when using Cy, to increasing d
52he TBI dose to 13 Gy. However, the limitations of
his study are such that we believe that a randomized
rial is warranted to address the issue of which is the
uperior conditioning regimen.
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